The pharma industry is traditionally an attractive sector with above average returns on investment (RoI) for shareholders. Manufacturing competition from China, India and Eastern Europe and rising patent challenges from generics firms are making it a tougher sector in which to do business, and a num...

The US Health and Human Services Department (HHS) has announced a new international initiative to enhance drug safety.

Chairman of the British Medical Association (BMA), Dr Hamish Meldrum, has called on the NHS to replace what he referred to as the ‘damaging’ market in the NHS, with a more cooperative Scottish healthcare model.

More than 50 per cent of people believe that in 10 years’ time the NHS will be charging for its services, according to a survey by the British Medical Association (BMA).

The Department of Health (DH) has unveiled a draft constitution, the first of its kind in the world, that ‘enshrines’ the principles and values of the NHS, an institution which it refers to as being too important to be left to chance.

The National Institute for Health and Clinical Excellence (NICE) has announced it is unable to recommend the use of Avastin for the treatment of breast and lung cancers on the NHS.

Health Secretary, Alan Johnson has announced that NHS patients will have the opportunity to participate in medical trials.

The New Year did not start well. Just 10 days in and an influential body of MPs called on the National Institute for Health and Clinical Excellence to lower the QALY threshold. One of the House of Commons Health Select Committee’s key recommendations was that the cost-per-quality adjusted life year ...

While drug makers are rapidly adapting to meet the tough times ahead, another part of the UK healthcare market is burgeoning and is expected to grow at an above average rate for at least the next five years. This ‘part’ of the industry is medical devices, diagnostics and technology.